anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound expressed by the formula (R represents glycoside group and/or galactosyl group; n is an integer of >=1). USE:An additive for foods and antitumor agent. PREPARATION:For example, sesame seeds are previously defatted, pulverized into less than 100 meshes, immersed in a water-methanol based solvent and agitated while heating to carry out extraction. A crude glycoside is obtained by vaporizing the solvent therefrom. The crude glycoside is then dissolved in chloroform and an equal amount of water is added thereto and vigorously stirred. A chloroform phase is separated therefrom and the solvent is distilled off to afford a chloroform-soluble fraction. Then acetone is added thereto, and after stirring, a supernatant liquid is removed to separate an acetone- insoluble fraction. The product is purified by column chromatography with a chloroform-methanol based solvent and a silica gel column, etc., to afford the compound expressed by the formula.
SURVANTA can rapidly affect oxygenation and lung compliance within minutes of administration of SURVANTA. Therefore, its use should be restricted to a highly supervised clinical setting with immediate availability of clinicians experienced with intubation, ventilator management, and general care of premature infants. Infants receiving SURVANTA should be frequently monitored with arterial or transcutaneous measurement of systemic oxygen and carbon dioxide. 

During the dosing procedure, transient episodes of bradycardia and decreased oxygen saturation have been reported. If these occur, stop the dosing procedure and initiate appropriate measures to alleviate the condition. After stabilization, resume the dosing procedure.
Systems and methods for detection, grading, scoring and tele-screening of cancerous lesions are described. A complete scheme for automated quantitative analysis and assessment of human and animal tissue images of several types of cancers is presented. Various aspects of the invention are directed to the detection, grading, prediction and staging of prostate cancer on serial sections/slides of prostate core images, or biopsy images. Accordingly, the invention includes a variety of sub-systems, which could be used separately or in conjunction to automatically grade cancerous regions. Each system utilizes a different approach with a different feature set. For instance, in the quantitative analysis, textural-based and morphology-based features may be extracted at image- and (or) object-levels from regions of interest.
Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 mg/kg followed by a 6 mg/kg in a 21-day cycle. Sirolimus was administered at a 6 mg oral daily dose. Cycles were repeated on an every 21 or 28-day schedule until disease progression, unacceptable toxicity, or the development of any of the criteria for study removal. Doses were reduced or discontinued based on tolerability.
A traditional Chinese medicine composition for treating rheumatism and its preparation method, the active prescription in the traditional Chinese medicine composition is composed of (by weight parts) Ningpo Yam rhizome extract 7-10, caulis Spatholobi extract 6-8, and Zingiberis rhizoma extract 2-5. The preparation method comprises the following steps: extracting rhizoma Discoreae Nipponicae and Zingiberis rhizoma with ethanol under reflux, adsorbing with resin, eluting, concentrating, and drying the eluate. Decocting caulis Spatholobi in water, and concentrating and drying to obtain water extractive solution. Mixing the extracts, adding medicinal adjuvants, and making into conventional dosage form to obtain the Chinese medicinal composition for treating rheumatism. The invention has the beneficial effects that: the active components are used as the medicine in the form of the extract of the active components, the active parts are complete, the compatibility of the active components and the regulation of the component proportion are clear, and the material basis is clear. Corresponding pharmacodynamic evaluation is carried out aiming at the migratory arthralgia in the rheumatic arthralgia, the action mechanism is clear, and the curative effect is obviously improved.
Those assigned to RE will complete baseline and post-testing assessments and participate in 12 weeks of individually-supervised resistance exercise, which will take place in the exercise facility on the Johns Hopkins Bayview Medical Center Campus. Exercises will be performed on Ren-Ex Machines. This equipment is suitable for the proposed study because it provides ultra-low friction movement which creates a personalized resistance profile, which minimizes force on joints and thereby reduces the risk of joint trauma and injury.
FIELD: medicine, prophylaxis. SUBSTANCE: at the first stage not later than one month before planned vaccination against influenza it is necessary to prescribe vaccine of bacterial origin, at its background one should introduce inactivated influenza vaccine in 1-3 mo against the onset of the abovementioned preparation intake. As vaccine of bacterial origin one should perorally introduce ribomunyl or intranasally - IRS-19. The present method enables to increase efficiency of immunization and decreases the risk in development of postvaccinal complications. EFFECT: higher efficiency of prophylaxis. 2 cl, 2 ex
The invention relates to a gaseous composition containing xenon as active ingredient for use in preventing or limiting tumour cell migration and/or limiting or preventing metastasis formation in an individual suffering from cancer. The prevention or limitation of tumour cell migration is obtained through the action of the xenon on free cancer cells. The xenon acts on the free cancer cells carried by the blood. The effective volume proportion of xenon is between 5% and 79%, it is preferably at least 50%. The gaseous composition also contains a volume proportion of oxygen (O2) of at least 21%. It is administered by inhalation or insufflation.
Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.
PURPOSE: To provide the compressing method for digital image data which reduces a transfer time and/or storage capacity. CONSTITUTION: An object image including digital image data is read in (step 1). The object image is modeled (step 2). The model for the object image is matched against an image obtained by modeling a standard reference image having relatively small correlation in three dimensions (step 3). Here, space adjustments of the image are made so as to correct deviations in position, scale, and direction. Namely, the corrections are so made that the modeled object image and reference image have correlation in spatial and spectrum dimensions. Differences between the modeled reference image and object image are calculated to form a difference image (step 4), which is compressed (step 5).
The invention belongs to the technical field of research on developmental endothelial cell gene-1, and particularly relates to application of Del-1 as a new biomarker and a therapeutic drug for inflammatory bowel diseases. Application of Del-1 and/or Del-1-Fc fusion protein in preparing medicines for preventing and treating inflammatory bowel diseases. Application of Del-1 and/or Del-1-Fc fusion protein in preparing preparation for inhibiting colitis intestinal inflammatory factor secretion. Application of the intestinal inflammatory factor in preparing a preparation for inhibiting Del-1 expression or Del-1-Fc expression. Application of the Del-1 detection agent in preparation of an inflammatory bowel disease detection preparation. The Del-1 and the fusion protein thereof have the effects of regulating and improving inflammatory bowel diseases; meanwhile, an adjustment scheme is also given for the adjustment of Del-1; and from another aspect provides a means of detection for inflammatory bowel disease detection.
PURPOSE:To provide an inorganic oxide having particular specific surface area and spherical form, and composed mainly of SiO2 and two or more kinds of metal oxide of the I -IV groups of he periodic table and capable of bonding with SiO2. CONSTITUTION:The objective inorganic oxide has a specific surface area of >=100m<2>/g and spherical form, and is composed mainly of SiO2 and two or more kinds of metallic oxides of the I -IV groups of the periodic table and capable of bonding with SiO2. A representative example of the preparation of the above oxide is as follows. A mixture containing (A) a hydrolyzable organic silicon compound and (B) two or more kinds of hydrolyzable organic compounds of metal of the I -IV groups is added to an alkaline solvent which dissolves the component (B) but does not dissove the reaction product. The reaction product obtained by th hydrolysis is precipitated from the solution. The main constituent component of the inorganic oxide is SiO2/(oxide of II-group element)/Ti, excluding the crystalline component.
Patients will receive approximately 30 minutes physiotherapy once daily in the ward delivered by the ward's usual physiotherapists i.e. starting on the first postoperative day and thereafter primarily on weekdays until discharge (a mean of 8.82 days after admission). Usual care physiotherapy is individualized taking the patients ability and previous level of functioning into account and includes 1) progressive functional training of basic mobility e.g. in-out of bed, sit-to-stand and walking including progression in walking aid, stair training if possible, and advices toward better physical functional level, 2) basic bed exercises with progression to standing exercises according to a hand-out training program and recommendations on doing exercises daily and being as physical active as possible during the day.
FIELD: organometallic chemistry. SUBSTANCE: invention relates to derivatives of sugars of the general formula (1)   where n = 1-6; residue of the formula (2)   means free radical containing mannose or fucose or N-acetylglucosamine as terminal nonreducing sugar bound at position C-1 carbon; Y means a bridge group presenting aliphatic hydrocarbon with carbon number from 1 to 6 in chain covalently bound with saccharide radical at position C-1 carbon by simple ether bond or through group -C(O)- and bound with metallocene by ester bond or through group -NH-C(O)-; CpMe means metallocene. Compounds show anti-infectious activity. Invention proposes also agent for activation of killing microorganisms located intracellularly and comprising compound of the formula (1) as active component. EFFECT: valuable antibacterial properties of compound. 4 cl, 2 dwg, 5 ex
Arformoterol, the (R,R)-enantiomer of formoterol, is a selective long-acting beta 2-adrenergic receptor agonist (beta 2-agonist) that has two-fold greater potency than racemic formoterol (which contains both the (S,S) and (R,R)-enantiomers). The (S,S)-enantiomer is about 1,000-fold less potent as a beta 2-agonist than the (R,R)-enantiomer. While it is recognized that beta 2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1-receptors are the predominant receptors in the heart, data indicate that there are also beta 2-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta 2-agonists may have cardiac effects. 

The pharmacologic effects of beta 2-adrenoceptor agonist drugs, including arformoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. 

In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans is unknown.
Part 1 - Assessment of treatment patterns, healthcare resource utilization and costs. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no skeletal-related events (SREs) in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before and at least 6 months after the index date.
PROBLEM TO BE SOLVED: To obtain a hair tonic cosmetic excellent in hair growing effect, preventing effect on loss of hair, a feeling in use and safety by using both an extract of tea leaves prepared by a specific treatment and an extract of Gentiana lutea Linne. SOLUTION: An extract of tea leaves obtained by preserving raw tea leaves under an anaerobic condition and heat-treating them with steam and/or in a dry state is combined with an extract of Gentiana lutea Linne. The amount of tea leaves mixed is about 0.0001-5.0wt.% calculated as an evaporation residue of the extract of tea leaves based on the total of the hair tonic cosmetic. As the extract of Gentiana lutea Linne, an extracted solution prepared by extracting a root and rhizome of Gentiana lutea Linne with water, ethanol, propylene glycol, 1,3-butylene glycol or its mixed solution and the evaporation residue prepared by concentrating the extracted solution to dryness. The amount of the extract of Gentiana lutea Linne mixed is about 0.0001-5.0wt.% calculated as the evaporation residue of the extract of Gentiana lutea Linne.  The cosmetic is excellent in hair tonic effect and hair growing effect free from tackiness and a squeaky feeling by synergistic effects of each component.
Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC.
<P>PROBLEM TO BE SOLVED: To provide a new means for treating cancer.  <P>SOLUTION: Expression of mortalin is upregulated in immortalized cells and tumor tissue. The immortalized human cell expressing mortalin at a high level exhibits anchorage independent propagation. By injecting K-antibody as a specific antimortalin antibody to tumors of nude mice, in comparison with its control group, tumor growth is suppressed or tumor is reduced. The specific antimortalin antibody (K-antibody) is used for treating tumor and is used as a carrier molecule for carrying immunotoxin, or the like, into cells. It is shown that the mortalin can be a target of tumor treatment. By this invention, a new effective anticancer agent is provided, and an antimortalin antibody internalized in a cell is developed. Several applications using the antibody are provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Belonging to the technical field of pharmaceutical preparations, the invention relates to a retigabine intragastric floating type sustained-release tablet and a preparation method thereof. The retigabine intragastric floating type sustained-release tablet is characterized in that it mainly includes a retigabine bulk drug and an HPMC macromolecular sustained-release material. The retigabine accounts for 50%-70% of the total tablet weight, and can continuously float for over 12h in artificial simulated gastric fluid. The invention aims to provide the retigabine intragastric floating type sustained-release tablet that has good patient compliance and small side effect and can persistently stabilize blood concentration. Another purpose of the invention is to provide the preparation method of the retigabine intragastric floating type sustained-release tablet. The preparation method has the advantages of good process reproducibility and high production efficiency, and the prepared retigabine intragastric floating type sustained-release tablet has good release homogeneity.
Nintedanib cloth sulfonate soft capsule treatment: According to the drug manual recommendation, give Nintedanib cloth sulfonate soft capsule 150mg twice daily with an interval of about 12 hours each time. Continuous medication for 8 weeks.
For patients in this group, a dose of penehyclidine (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
BACKGROUND: Accurate identification of delirium in sepsis patients is crucial for guiding clinical diagnosis and treatment. However, there are no accurate biomarkers and indicators at present. We aimed to identify which combinations of cognitive impairment-related biomarkers and other easily accessible assessments best predict delirium in sepsis patients.
METHODS: One hundred and one sepsis patients were enrolled in a prospective study cohort. S100B, NSE, and BNIP3 L biomarkers were detected in plasma and cerebrospinal fluid and patients' optic nerve sheath diameter (ONSD). The optimal biomarkers identified by Logistic regression are combined with other factors such as ONSD to filter out the perfect model to predict delirium in sepsis patients through Logistic regression, Naïve Bayes, decision tree, and neural network models.
MAIN RESULTS: Among all biomarkers, compared with BNIP3 L (AUC = .706, 95% CI = .597-.815) and NSE (AUC = .711, 95% CI = .609-.813) in cerebrospinal fluid, plasma S100B (AUC = .729, 95% CI = .626-.832) had the best discrimination performance for delirium in sepsis patients. Logistic regression analysis showed that the combination of cerebrospinal fluid BNIP3 L with plasma S100B, ONSD, neutrophils, and age provided the best discrimination to cognitive impairment in sepsis patients (accuracy = .901, specificity = .923, sensitivity = .911), which was better than Naïve Bayes, decision tree, and neural network models. Neutrophils, ONSD, and cerebrospinal fluid BNIP3 L were consistently the major contributors in a few models.
CONCLUSIONS: The logistic regression showed that the combination model was strongly correlated with cognitive dysfunction in sepsis patients.
The invention belongs to the technical field of personal hygiene and occupational protection, and particularly relates to an antiviral traditional Chinese medicine composition and a mask. The traditional Chinese medicine composition comprises the following medicines in parts by weight: 150 parts of folium artemisiae argyi 120-. As one application mode of the external medicine, the invention also discloses a novel mask prepared from the traditional Chinese medicine composition. The mask can effectively block the spread of epidemic diseases caused by viruses when being worn for a long time. The traditional Chinese medicine composition and the mask have good application prospects. Therefore, the traditional Chinese medicine composition and the mask have good application prospects.
During the active weight loss period, the TRE group will be instructed to eat ad libitum from 12:00pm - 8:00pm daily and fast from 8:00pm - 12:00pm. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, participants will be encouraged to drink plenty of water and may consume energy-free beverages, such as black tea or coffee. TRE subjects will meet with the TRE dietitian for 30 minutes at the start of the intervention to review instructions and goals, and then every week throughout the active weight loss period to review intervention adherence. At the beginning of the maintenance phase, total energy needs will be reassessed. Subjects will be instructed to main their body weight by consuming meals in an extended 10-h eating window every day and water fast between 8pm and 10 am, respectively.
FIELD: cosmetics. SUBSTANCE: solvent is infusion in water of schungite of group III A. For preparing solvent, schungite is ground with fraction size 1.5-20 mm in ratio with water 1:1, aged at room temperature for 2-3 days at periodic mixing. After that, infusion is drained and evaporated at atmospheric pressure reducing the volume half as much. Then infusion is mixed with the same mineral schungite with fraction size 40-80 mm in ratio 1:1, aged at room temperature for 4-5 days without mixing, and ready-prepared infusion is drained. At transportation or long storage of solvent, schungite with fraction size 15-25 mm is used as preservative, placed in package in amount of 5-10% from solvent volume. EFFECT: higher efficiency. 4 cl
Patients with low-risk or intermediate-risk, clinically localized prostate cancer will be evaluated according to standard of care medical practices. The evaluation includes history and examination, prostate-specific antigen (PSA) blood testing, and review of the prior prostate biopsy pathology report; radiology scans (for example, computed tomography \[CT\], magnetic resonance imaging \[MRI\], radionuclide bone scan) may be done also; recently completed testing may not need to be repeated. Small markers will be placed in the prostate to guide the proton beam stereotactic ablative body radiotherapy (SABR) treatments, and a hydrogel spacer may also be placed between the prostate and the rectum to push the rectum away from the prostate; the hydrogel spacer will dissolve a few months later. Participants will receive five (5) proton SABR treatments over a two (2) week time period. The study will have participants complete a quality-of life questionnaire and be evaluated for side-effects before starting SABR, at the end of SABR, at three (3), six (6) and 12 months after SABR, and then yearly for five (5) years. Evaluation of the cancer status will follow standard of care practices for at least ten (10) years.
A system for a virtual integrated remote assistant is provided. In some implementations, the system performs operations comprising receiving an input for a surgical procedure. The operations further include determining first feedback for the surgical procedure. The operations further include receiving, in response to the first feedback, a user input. The operations further include receiving second feedback from a laser apparatus. The operations further include performing eye tracking verification for a user. The operations further include displaying a graphical display of a virtual assistant. Related systems, methods, and articles of manufacture are also described.